NCT01546987 2026-03-06
Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer
Radiation Therapy Oncology Group
Phase 3 Completed
Clinical Trials
126 trialsNCT00063882 2026-03-05
Interstitial Brachytherapy With or Without External-Beam Radiation Therapy in Treating Patients With Prostate Cancer
Radiation Therapy Oncology Group
Phase 3 Completed
NCT04736199 2026-02-27
ARANOTE
Bayer
Phase 3 Completed
NCT04689828 2026-02-20
PSMAfore
Novartis
Phase 3 Active not recruiting
NCT02257736 2026-02-13
An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)
Aragon Pharmaceuticals, Inc.
Phase 3 Active not recruiting
NCT01946204 2026-02-02
SPARTAN
Aragon Pharmaceuticals, Inc.
Phase 3 Active not recruiting
NCT02489318 2026-02-02
TITAN
Aragon Pharmaceuticals, Inc.
Phase 3 Active not recruiting
NCT02003924 2026-01-27
PROSPER
Pfizer
Phase 3 Completed
NCT04647526 2026-01-13
SPLASH
Eli Lilly and Company
Phase 3 Active not recruiting
NCT01809691 2025-12-31
S1216
SWOG Cancer Research Network
Phase 3 Completed
NCT04446117 2025-12-18
CONTACT-02
Exelixis
Phase 3 Active not recruiting
NCT04838613 2025-10-20
GuidePath
Novartis
Phase 3 Completed
NCT04186845 2025-09-22
Imaging Study to Investigate Safety and Diagnostic Performance of 18F rhPSMA 7.3 PET Ligand in Suspected Prostate Cancer Recurrence
Blue Earth Diagnostics
Phase 3 Completed
NCT05590793 2025-09-09
Effects of Triptorelin Pamoate 6-month When Given to Adult Chinese Participants With Advanced Cancer in the Prostate
Ipsen
Phase 3 Completed
NCT03834493 2025-07-18
KEYNOTE-641
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT03834506 2025-07-18
KEYNOTE-921
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT05547386 2025-07-18
68Ga-PSMA-11 PET/CT Screening Prior to 177Lu-PSMA-617 Therapy for Patients With Metastatic Castrate Resistant Prostate Cancer
Mayo Clinic
Phase 3 Completed
NCT02319837 2025-07-08
Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)
Pfizer
Phase 3 Active not recruiting
NCT05288166 2025-06-27
CYCLONE 3
Eli Lilly and Company
Phase 3 Active not recruiting
NCT04100018 2025-06-12
CheckMate 7DX
Bristol-Myers Squibb
Phase 3 Completed
NCT03072238 2025-06-06
IPATential150
Hoffmann-La Roche
Phase 3 Completed
NCT03834519 2025-05-18
KEYLYNK-010
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT00567580 2025-05-09
Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising Prostate Specific Antigen (PSA) After Surgery for Prostate Cancer
Radiation Therapy Oncology Group
Phase 3 Active not recruiting
NCT01220869 2025-04-13
A Study of Degarelix in Taiwanese Patients With Prostate Cancer
Ferring Pharmaceuticals
Phase 3 Completed
NCT02288247 2025-04-08
PRESIDE
Astellas Pharma Inc
Phase 3 Completed
NCT04186819 2025-02-26
Imaging Study to Investigate the Safety and Diagnostic Performance of rhPSMA 7.3 (18F) in Newly Diagnosed Prostate Cancer.
Blue Earth Diagnostics
Phase 3 Completed
NCT02043678 2025-02-19
ERA 223
Bayer
Phase 3 Completed
NCT00887198 2025-02-04
Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer
Janssen Research & Development, LLC
Phase 3 Completed
NCT01715285 2025-02-04
A Study of Abiraterone Acetate Plus Low-Dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Participants With High-Risk, Metastatic Hormone-Naive Prostate Cancer (mHNPC)
Janssen Research & Development, LLC
Phase 3 Completed
NCT03511664 2025-01-13
VISION
Endocyte
Phase 3 Completed
NCT03056638 2024-08-28
Trial of ADT and SBRT Versus SBRT for Intermediate Prostate Cancer
Memorial Sloan Kettering Cancer Center
Phase 3 Terminated
NCT04907227 2024-07-12
KEYNOTE-921
Merck Sharp & Dohme LLC
Phase 3 Terminated
NCT04887506 2024-01-16
TAVT-45 (Abiraterone Acetate) Granules in Patients With Prostate Cancer
Tavanta Therapeutics
Phase 3 Completed
NCT00942331 2023-10-16
Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer
National Cancer Institute (NCI)
Phase 3 Completed
NCT01949337 2023-09-28
Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer
Alliance for Clinical Trials in Oncology
Phase 3 Unknown
NCT01238172 2023-03-21
Diet in Altering Disease Progression in Patients With Prostate Cancer on Active Surveillance
Alliance for Clinical Trials in Oncology
Phase 3 Completed
NCT00430183 2023-02-09
Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate Cancer
Alliance for Clinical Trials in Oncology
Phase 3 Active not recruiting
NCT00033631 2023-01-18
Radiation Therapy in Treating Patients With Stage II Prostate Cancer
Radiation Therapy Oncology Group
Phase 3 Completed
NCT00004124 2022-12-30
S9921, Hormone Therapy With or Without Mitoxantrone and Prednisone in Patients Who Have Undergone Radical Prostatectomy for Prostate Cancer
SWOG Cancer Research Network
Phase 3 Completed
NCT00377156 2022-09-16
Stereotactic Radiation Therapy With or Without Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
Alliance for Clinical Trials in Oncology
Phase 3 Completed
NCT02663908 2022-06-29
PRONOUNCE
Ferring Pharmaceuticals
Phase 3 Terminated
NCT00288080 2022-06-21
Hormone Therapy and Radiation Therapy or Hormone Therapy and Radiation Therapy Followed by Docetaxel and Prednisone in Treating Patients With Localized Prostate Cancer
Radiation Therapy Oncology Group
Phase 3 Completed
NCT02352103 2022-02-25
Impact of Robot-assisted Radical Prostatectomy Technique on Short-term Continence Recovery
Henry Ford Health System
Phase 3 Completed
NCT03085095 2022-01-18
HERO
Myovant Sciences GmbH
Phase 3 Completed
NCT00134056 2021-10-27
S0421, Docetaxel and Prednisone With or Without Atrasentan in Treating Patients With Stage IV Prostate Cancer and Bone Metastases That Did Not Respond to Previous Hormone Therapy
SWOG Cancer Research Network
Phase 3 Completed
NCT03353740 2021-10-21
Gallium-68 PSMA-11 Positron Emission Tomography (PET) Imaging in Patients With Biochemical Recurrence
University of California, San Francisco
Phase 3 Completed
NCT00354432 2021-09-28
Soy Protein/Effexor Hormone Therapy for Prostate Cancer
Wake Forest University Health Sciences
Phase 3 Terminated
NCT03803475 2021-08-24
Gallium-68 PSMA-11 PET Imaging in Prostate Cancer Patients
University of California, San Francisco
Phase 3 Completed
NCT02057666 2021-04-23
TasQ003
Ipsen
Phase 3 Terminated
NCT02111577 2021-04-06
VIABLE
Sotio Biotech Inc.
Phase 3 Completed